S

Shanghai Kinetic Medical Co Ltd
SZSE:300326

Watchlist Manager
Shanghai Kinetic Medical Co Ltd
SZSE:300326
Watchlist
Price: 6.58 CNY -2.08% Market Closed
Market Cap: 4.7B CNY
Have any thoughts about
Shanghai Kinetic Medical Co Ltd?
Write Note

Shanghai Kinetic Medical Co Ltd
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shanghai Kinetic Medical Co Ltd
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai Kinetic Medical Co Ltd
SZSE:300326
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Cash Equivalents
ÂĄ1.7B
CAGR 3-Years
-49%
CAGR 5-Years
-34%
CAGR 10-Years
N/A
J
Jafron Biomedical Co Ltd
SZSE:300529
Cash Equivalents
ÂĄ6m
CAGR 3-Years
N/A
CAGR 5-Years
-46%
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Cash Equivalents
ÂĄ178.4k
CAGR 3-Years
109%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shanghai Kinetic Medical Co Ltd
Glance View

Market Cap
4.7B CNY
Industry
Health Care

Shanghai Kinetic Medical Co., Ltd. engages in the research, development, manufacture and sale of medical devices dedicated to serve orthopedic minimally invasive surgerical needs. The company is headquartered in Shanghai, Shanghai and currently employs 1,107 full-time employees. The company went IPO on 2012-06-13. The firm is mainly engaged in the research, development, manufacture and sale of minimally invasive interventional surgical systems for vertebroplasty, the research, development, manufacture and sale of orthopedic medical devices, such as orthopedic implants and orthopedic surgical instruments, as well as the development, manufacture and sale of drug-eluting coronary stents. The firm operates its business in domestic market.

Intrinsic Value
6 CNY
Overvaluation 9%
Intrinsic Value
Price
S

See Also

Back to Top